Comparing the Nucleocapsid Proteins of Human Coronaviruses: Structure, Immunoregulation, Vaccine, and Targeted Drug

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2022 May 16

PMID 35573742

Authors

Bo Zhang

Junjie Tian

Qintao Zhang

Yan Xie

Kejia Wang

Shuyi Qiu

Keyu Lu

Yang Liu

Affiliations

Soon will be listed here.

Abstract

The seven pathogenic human coronaviruses (HCoVs) include HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, which usually cause mild upper respiratory tract diseases, and SARS-CoV, MERS-CoV, and SARS-CoV-2, which cause a severe acute respiratory syndrome. The nucleocapsid (N) protein, as the dominant structural protein from coronaviruses that bind to the genomic RNA, participates in various vital activities after virus invasion and will probably become a promising target of antiviral drug design. Therefore, a comprehensive literature review of human coronavirus' pathogenic mechanism and therapeutic strategies is necessary for the control of the pandemic. Here, we give a systematic summary of the structures, immunoregulation, and potential vaccines and targeted drugs of the HCoVs N protein. First, we provide a general introduction to the fundamental structures and molecular function of N protein. Next, we outline the N protein mediated immune regulation and pathogenesis mechanism. Finally, we comprehensively summarize the development of potential N protein-targeted drugs and candidate vaccines to treat coronavirus disease 2019 (COVID-19). We believe this review provides insight into the virulence and transmission of SARS-CoV-2 as well as support for further study on epidemic control of COVID-19.

Citing Articles

Nucleocapsid Protein of SARS-CoV-2 Upregulates RANTES Expression in A172 Glioblastoma Cells.

Gadilgereyeva B, Kunushpayeva Z, Abdrakhmanova M, Khassenova A, Minigulov N, Burster T Molecules. 2025; 30(5).

PMID: 40076291 PMC: 11902235. DOI: 10.3390/molecules30051066.

Investigation of Long-Term CD4+ T Cell Receptor Repertoire Changes Following SARS-CoV-2 Infection in Patients with Different Severities of Disease.

Callery E, Morais C, Taylor J, Challen K, Rowbottom A Diagnostics (Basel). 2024; 14(20).

PMID: 39451653 PMC: 11507081. DOI: 10.3390/diagnostics14202330.

SARS-CoV-2 natural infection, but not vaccine-induced immunity, elicits cross-reactive immunity to OC43.

Garziano M, Cano Fiestas M, Vanetti C, Strizzi S, Murno M, Clerici M Heliyon. 2024; 10(19):e37928.

PMID: 39391514 PMC: 11466580. DOI: 10.1016/j.heliyon.2024.e37928.

Insights into the Activation of Unfolded Protein Response Mechanism during Coronavirus Infection.

Keramidas P, Pitou M, Papachristou E, Choli-Papadopoulou T Curr Issues Mol Biol. 2024; 46(5):4286-4308.

PMID: 38785529 PMC: 11120126. DOI: 10.3390/cimb46050261.

Epitopes recognition of SARS-CoV-2 nucleocapsid RNA binding domain by human monoclonal antibodies.

Kim Y, Maltseva N, Tesar C, Jedrzejczak R, Endres M, Ma H iScience. 2024; 27(2):108976.

PMID: 38327783 PMC: 10847736. DOI: 10.1016/j.isci.2024.108976.

References

Chen K, Xiao F, Hu D, Ge W, Tian M, Wang W . SARS-CoV-2 Nucleocapsid Protein Interacts with RIG-I and Represses RIG-Mediated IFN-β Production. Viruses. 2021; 13(1). PMC: 7823417. DOI: 10.3390/v13010047. View

Cui L, Wang H, Ji Y, Yang J, Xu S, Huang X . The Nucleocapsid Protein of Coronaviruses Acts as a Viral Suppressor of RNA Silencing in Mammalian Cells. J Virol. 2015; 89(17):9029-43. PMC: 4524063. DOI: 10.1128/JVI.01331-15. View

Dutta N, Mazumdar K, Gordy J . The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94(13). PMC: 7307180. DOI: 10.1128/JVI.00647-20. View

Baral P, Bhattarai N, Hossen M, Stebliankin V, Gerstman B, Narasimhan G . Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion. Biochem Biophys Res Commun. 2021; 574:14-19. PMC: 8364676. DOI: 10.1016/j.bbrc.2021.08.036. View

Surjit M, Lal S . The SARS-CoV nucleocapsid protein: a protein with multifarious activities. Infect Genet Evol. 2007; 8(4):397-405. PMC: 7106238. DOI: 10.1016/j.meegid.2007.07.004. View

Luo H, Wu D, Shen C, Chen K, Shen X, Jiang H . Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction. Int J Biochem Cell Biol. 2005; 38(4):589-99. PMC: 7108423. DOI: 10.1016/j.biocel.2005.10.022. View

Tang F, Quan Y, Xin Z, Wrammert J, Ma M, Lv H . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011; 186(12):7264-8. DOI: 10.4049/jimmunol.0903490. View

Zhang S, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A . Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2009; 226:29-40. DOI: 10.1111/j.1600-065X.2008.00698.x. View

Tylor S, Andonov A, Cutts T, Cao J, Grudesky E, Van Domselaar G . The SR-rich motif in SARS-CoV nucleocapsid protein is important for virus replication. Can J Microbiol. 2009; 55(3):254-60. DOI: 10.1139/w08-139. View

10.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

11.

Papanicolaou D, Wilder R, Manolagas S, Chrousos G . The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 1998; 128(2):127-37. DOI: 10.7326/0003-4819-128-2-199801150-00009. View

12.

Rana A, Rahmatkar S, Kumar A, Singh D . Glycogen synthase kinase-3: A putative target to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Cytokine Growth Factor Rev. 2020; 58:92-101. PMC: 7446622. DOI: 10.1016/j.cytogfr.2020.08.002. View

13.

Roark R, Li H, Williams W, Chug H, Mason R, Gorman J . Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science. 2020; 371(6525). PMC: 8040783. DOI: 10.1126/science.abd2638. View

14.

Wang C, Horby P, Hayden F, Gao G . A novel coronavirus outbreak of global health concern. Lancet. 2020; 395(10223):470-473. PMC: 7135038. DOI: 10.1016/S0140-6736(20)30185-9. View

15.

Ng O, Chia A, Tan A, Jadi R, Leong H, Bertoletti A . Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016; 34(17):2008-14. PMC: 7115611. DOI: 10.1016/j.vaccine.2016.02.063. View

16.

Ferretti A, Kula T, Wang Y, Nguyen D, Weinheimer A, Dunlap G . Unbiased Screens Show CD8 T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity. 2020; 53(5):1095-1107.e3. PMC: 7574860. DOI: 10.1016/j.immuni.2020.10.006. View

17.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

18.

Matloubian M, Concepcion R, Ahmed R . CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol. 1994; 68(12):8056-63. PMC: 237269. DOI: 10.1128/JVI.68.12.8056-8063.1994. View

19.

Altmann D, Boyton R . SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection. Sci Immunol. 2020; 5(49). DOI: 10.1126/sciimmunol.abd6160. View

20.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View